FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an immunostimulatory oligonucleotide stimulating the toll-like receptor 21 (TLR21), a vaccine for the prevention or treatment of Newcastle disease, an expression vector, an immunostimulatory composition for stimulating the toll-like receptor 21 (TLR21), a method for stimulating the toll-like receptor 21 ( TLR21) and a toll-like receptor 21 (TLR21) mediated immune response method. In one embodiment, the immunostimulatory oligonucleotide comprises at least one CpG motif and a guanine-enriched sequence.
EFFECT: invention expands the arsenal of agents stimulating TLR21.
7 cl, 79 dwg, 65 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOSTIMULATING COMPOSITIONS | 2018 |
|
RU2799523C1 |
| COMBINED PURIFICATION AND MEASUREMENT OF DNA METHYLATION WITH COMBINED MEASUREMENT OF MUTATIONS AND/OR LEVELS OF mRNA EXPRESSION IN AUTOMATED REACTION CARTRIDGE | 2017 |
|
RU2780660C2 |
| GENOME-WIDE LIBRARIES OF INDIVIDUAL CELLS FOR BISULFITE SEQUENCING | 2018 |
|
RU2770879C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| DELIVERY, USE AND USE IN THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETED ACTION ON DISORDERS AND DISEASES USING VIRAL COMPONENTS | 2014 |
|
RU2716421C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| COMPOSITIONS AND METHODS OF TREATING HEMOGLOBINOPATHIES | 2016 |
|
RU2812491C2 |
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| MODIFIED OLIGONUCLEOTIDES AND METHODS OF THEIR USE | 2017 |
|
RU2802836C2 |
